Vorinostat in cutaneous T-CELL lymphoma

被引：46

作者：

Duvic, Madeleine ^{[1
]}

Vu, Jenny ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

DRUGS OF TODAY | 2007年 / 43卷 / 09期

关键词：

D O I：

10.1358/dot.2007.43.9.1112980

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Histone deacetylase inhibitors (HDAC-Is) are a novel class of small molecules being evaluated in clinical trials for a number of different malignancies. HDAC-Is are able to induce differentiation, apoptosis and/or cell cycle arrest of malignant cells selectively. Vorinostat (Zolinza (TM), Merck & Co., Whitehouse Station, NJ, USA) is the first HDAC-I approved by the U.S. Food and Drug Administration for treatment of the cutaneous manifestations in patients with cutaneous T-cell lymphoma ((CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. Vorinostat was active against solid-tumors and hematologic malignancies as intravenous and oral preparations in phase I development. In two phase 11 trials, Vorinostat was safe and effective at an oral dose of 400 mg/day with an overall response rate of 30-31% in refractory advanced patients with CTCL including large cell transformation and Sezary syndrome. The most frequent side effects of vorinostat include gastrointestinal symptoms, fatigue and thrombocytopenia. Vorinostat, in combination with other agents such as radiation therapy and chemotherapy, can have synergistic or additive effects in a variety of cancers in clinical trials. (C) 2007 Prous Science. All rights reserved.

引用

页码：585 / 599

页数：15

共 68 条

[11]

Cohen LA, 1999, ANTICANCER RES, V19, P4999

[12]

Cohen LA, 2002, ANTICANCER RES, V22, P1497

[13] Histone deacetylases (HDACs): characterization of the classical HDAC family [J].

De Ruijter, AJM ;

Van Gennip, AH ;

Caron, HN ;

Kemp, S ;

Van Kuilenburg, ABP .

BIOCHEMICAL JOURNAL, 2003, 370 :737-749

[14] Treatment of patch and plaque stage mycosis fungoides with imiuquimod 5% cream [J].

Deeths, MJ ;

Chapman, JT ;

Dellavalle, RP ;

Zeng, C ;

Aeling, JL .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (02) :275-280

[15]

Desai D, 2003, ANTICANCER RES, V23, P499

[16] Primary Sezary syndrome commonly shows low-grade cytologic atypia and an absence of epidermotropism [J].

Diwan, AH ;

Prieto, VG ;

Herling, M ;

Duvic, M ;

Jones, D .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 123 (04) :510-515

[17] Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma [J].

Duvic, M. ;

Zhang, C. .

BRITISH JOURNAL OF CANCER, 2006, 95 (Suppl 1) :S13-S19

[18] Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL) [J].

Duvic, Madeleine ;

Talpur, Rakshandra ;

Ni, Xiao ;

Zhang, Chunlei ;

Hazarika, Parul ;

Kelly, Cecilia ;

Chiao, Judy H. ;

Reilly, John F. ;

Ricker, Justin L. ;

Richon, Victoria M. ;

Frankel, Stanley R. .

BLOOD, 2007, 109 (01) :31-39

[19]

Furumai R, 2002, CANCER RES, V62, P4916

[20]

Garcia-Manero G, 2005, BLOOD, V106

← 1 2 3 4 5 6 7 →